4.6 Article

Anticholinergic Drugs Rescue Synaptic Plasticity in DYT1 Dystonia: Role of M1 Muscarinic Receptors

Journal

MOVEMENT DISORDERS
Volume 29, Issue 13, Pages 1655-1665

Publisher

WILEY
DOI: 10.1002/mds.26009

Keywords

dystonia; striatum; muscarinic receptor antagonists; synaptic plasticity

Funding

  1. Ministero Salute [RF-2010-2311657]
  2. Dystonia Medical Research Foundation (DMRF)
  3. Federation for Dystonia Research (FDR)
  4. Italian Ministry of Instruction, University and Research (PRIN)
  5. Italian Ministry of Instruction, University and Research (FIRB)
  6. COST (European Cooperation in Science and Technology) Action [BM1101]
  7. NIMH
  8. NIH Common fund

Ask authors/readers for more resources

Broad-spectrum muscarinic receptor antagonists have represented the first available treatment for different movement disorders such as dystonia. However, the specificity of these drugs and their mechanism of action is not entirely clear. We performed a systematic analysis of the effects of anticholinergic drugs on short- and long-term plasticity recorded from striatal medium spiny neurons from DYT1 dystonia knock-in (Tor1a(+/gag)) mice heterozygous for E-torsinA and their controls (Tor1a(+/+) mice). Antagonists were chosen that had previously been proposed to be selective for muscarinic receptor subtypes and included pirenzepine, trihexyphenydil, biperiden, orphenadrine, and a novel selective M-1 antagonist, VU0255035. Tor1a(+/gag) mice exhibited a significant impairment of corticostriatal synaptic plasticity. Anticholinergics had no significant effects on intrinsic membrane properties and on short-term plasticity of striatal neurons. However, they exhibited a differential ability to restore the corticostriatal plasticity deficits. A complete rescue of both long-term depression (LTD) and synaptic depotentiation (SD) was obtained by applying the M-1-preferring antagonists pirenzepine and trihexyphenidyl as well as VU0255035. Conversely, the nonselective antagonist orphenadrine produced only a partial rescue of synaptic plasticity, whereas biperiden and ethopropazine failed to restore plasticity. The selectivity for M-1 receptors was further demonstrated by their ability to counteract the M-1-dependent potentiation of N-methyl-d-aspartate (NMDA) current recorded from striatal neurons. Our study demonstrates that selective M-1 muscarinic receptor antagonism offsets synaptic plasticity deficits in the striatum of mice with the DYT1 dystonia mutation, providing a potential mechanistic rationale for the development of improved antimuscarinic therapies for this movement disorder. (c) 2014 International Parkinson and Movement Disorder Society

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family

Fubo Cheng, Wenxu Zheng, Peter Antony Barbuti, Paola Bonsi, Change Liu, Nicolas Casadei, Giulia Ponterio, Maria Meringolo, Jakob Admard, Claire Marie Dording, Libo Yu-Taeger, Huu Phuc Nguyen, Kathrin Grundmann-Hauser, Thomas Ott, Henry Houlden, Antonio Pisani, Rejko Kruger, Olaf Riess

Summary: Using epigenetic and transcriptomic approaches combined with multiple model systems, Cheng et al. show that mutations in THAP1 give rise to DYT6 dystonia via dysregulation of genes within the SP1 family. The latter could serve as therapeutic targets for a range of neurological diseases.

BRAIN (2022)

Article Neurosciences

Postsynaptic autism spectrum disorder genes and synaptic dysfunction

Paola Bonsi, Antonella De Jaco, Laurent Fasano, Paolo Gubellini

Summary: This review provides an overview of the synaptic dysfunction caused by mutations in autism spectrum disorder (ASD)-linked genes affecting the postsynaptic neuronal compartment. The effects of ASD-associated genes can vary depending on developmental time and subcellular site of expression. Better modeling ASD in experimental animals is needed to improve understanding of these disorders and increase the translational value of preclinical studies.

NEUROBIOLOGY OF DISEASE (2022)

Review Biochemistry & Molecular Biology

Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission

Martina Montanari, Giuseppina Martella, Paola Bonsi, Maria Meringolo

Summary: Disturbances in the glutamatergic system have been observed in autism spectrum disorder (ASD). This review summarizes evidence from patient samples, postmortem studies, and animal models to explore the role of glutamate in the pathophysiology of ASD and its potential as a therapeutic target.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Clinical Neurology

Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction

Giulia Ponterio, Gaia Faustini, Ilham El Atiallah, Giuseppe Sciamanna, Maria Meringolo, Annalisa Tassone, Paola Imbriani, Silvia Cerri, Giuseppina Martella, Paola Bonsi, Arianna Bellucci, Antonio Pisani

Summary: This study reveals the relationship between TA and alpha-Syn and demonstrates that alterations in alpha-Syn and SNAREs characterize the synaptic dysfunction underlying DYT1 dystonia.

MOVEMENT DISORDERS (2022)

Article Biochemistry & Molecular Biology

Pattern of Mitochondrial Respiration in Peripheral Blood Cells of Patients with Parkinson's Disease

Tommaso Schirinzi, Illari Salvatori, Henri Zenuni, Piergiorgio Grillo, Cristiana Valle, Giuseppina Martella, Nicola Biagio Mercuri, Alberto Ferri

Summary: A study found that mitochondrial respiratory activity increases in the blood leukocytes of Parkinson's disease (PD) patients, possibly as compensatory adaptations to disease progression. This finding, which is correlated with clinical features and cerebrospinal fluid biomarkers, provides preliminary evidence for further exploration of PD treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Neurosciences

Oxidative stress and synaptic dysfunction in rodent models of Parkinson's disease

Paola Imbriani, Giuseppina Martella, Paola Bonsi, Antonio Pisani

Summary: Parkinson's disease (PD) is a multifactorial disorder with genetic and environmental factors playing a part. Mitochondrial impairment and oxidative stress are important mechanisms in PD, supported by PD-associated genes involved in mitochondrial function. Dysfunction of mitochondria is closely linked to synaptic dysfunction, which is an early event before nigrostriatal neurodegeneration in PD.

NEUROBIOLOGY OF DISEASE (2022)

Article Multidisciplinary Sciences

A red nucleus-VTA glutamate pathway underlies exercise reward and the therapeutic effect of exercise on cocaine use

Yi He, Graziella Madeo, Ying Liang, Cindy Zhang, Briana Hempel, Xiaojie Liu, Lianwei Mu, Shui Liu, Guo-Hua Bi, Ewa Galaj, Hai-Ying Zhang, Hui Shen, Ross A. McDevitt, Eliot L. Gardner, Qing-Song Liu, Zheng-Xiong Xi

Summary: Physical exercise activates a specific neural pathway, producing exercise reward and reducing cocaine intake. The increased activity of a specific part of the red nucleus is associated with the projection to dopamine neurons.

SCIENCE ADVANCES (2022)

Review Biochemistry & Molecular Biology

Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson

Annalisa Tassone, Maria Meringolo, Giulia Ponterio, Paola Bonsi, Tommaso Schirinzi, Giuseppina Martella

Summary: Strong evidence suggests that the decline in mitochondrial function is correlated with degenerative diseases. Various types of neurodegenerative diseases, such as Huntington's chorea and Parkinson's disease, share mitochondrial bioenergy dysregulation as a common feature. These diseases have different manifestations and genetic factors, but they both involve neuronal dysfunction and striatal impairment. This review focuses on describing the onset and development of both diseases in relation to mitochondrial dysfunction.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson's Disease from Mice to Human

Martina Montanari, Paola Imbriani, Paola Bonsi, Giuseppina Martella, Antonella Peppe

Summary: The enteric nervous system (ENS), composed of neurons and glial cells, regulates the motor and secretory functions of the gastrointestinal tract. Dysfunction of the connections between the brain and the GI tract is implicated in Parkinson's disease (PD). Alterations in the ENS, including α-synuclein aggregation, occur early in the disease and spread to the central nervous system. This review highlights the role of the ENS in PD pathogenesis and its potential as a target for new therapeutic approaches.

BIOMEDICINES (2023)

Review Neurosciences

Synaptic Dysfunction in Dystonia: Update From Experimental Models

Ilham El Atiallah, Paola Bonsi, Annalisa Tassone, Giuseppina Martella, Gerardo Biella, Antonio N. Castagno, Antonio Pisani, Giulia Ponterio

Summary: This review discusses the expanded understanding of molecular mechanisms underlying dystonia through animal models in recent years, emphasizing the common synaptic alterations found in different forms of dystonia. Particularly, the abnormal motor network and synaptic dysfunction are key elements in the pathophysiology of dystonia.

CURRENT NEUROPHARMACOLOGY (2023)

Editorial Material Biochemistry & Molecular Biology

Molecular Mechanisms of Synaptic Plasticity 2.0: Dynamic Changes in Neurons Functions, Physiological and Pathological Process

Giuseppina Martella

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

No Data Available